


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
LASR
nLIGHT
$35.43
Strengths

Earnings are forecast to grow
Risk Analysis

Investors losing their confidence
LASR Price Performance
$29.48 (+20.18%)
$31.18 (+13.63%)
$19.51 (+81.60%)
$10.46 (+238.72%)
LASR has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

LASR overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow
![]()
LASR Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
LASR Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
Login to displayWhat is LASR current stock price?
What are LASR stock strengths?
What is LASR Risk Level?
What is LASR market cap and volume?
What is LASR current Stock IQ?
Should I buy LASR stock right now?
Is LASR a Strong Buy right now?
What does a 'Strong Buy' rating mean for LASR?
What does a 'Strong Sell' rating mean for LASR?
What factors influence LASR's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
LASR
nLIGHT
Current Price
$35.43
Stock Insights
Strengths

Earnings are forecast to grow
Risk Analysis

Investors losing their confidence

LASR Price Performance
$29.48 (+20.18%)
$31.18 (+13.63%)
$19.51 (+81.60%)
$10.46 (+238.72%)
LASR Analysts Opinion
LASR Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors losing their confidence
Future
Future

Earnings are forecast to grow
![]()
LASR Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
LASR Street Sentiment is extremely bullish and have positive views on the near-term outlook
LASR has Extreme risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
LASR Stock IQ
LASR Latest Analysis
Tesla Rival Xpeng Receives Level 3 Autonomous Testing Permit Amid Planned Robotaxi Push: Report. Chinese automaker ) has reportedly received a major boost in its Robotaxi ambitions as Chinese authorities greenlight autonomous driving testing.Authorities have granted the company a permit to conduct testing operations for Level 3 autonomous vehicles Chinese local media outlet Yicai reported on Tuesday. The company has received the permit to conduct testing operations in the city of Xpeng didn'
Today
nLight (LASR) Upgraded to Buy: What Does It Mean for the Stock?. nLight (LASR) has been upgraded to a Zacks Rank #2 (Buy) reflecting growing optimism about the companys earnings prospects. This might drive the stock higher in the near term.
Fri Dec 12, 2025
Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity - Slideshow.
Thu Dec 11, 2025
Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Data from INLIGHT Trial of WVE-007 for Obesity Transcript.
Mon Dec 8, 2025
Wave To Unveil Interim Data From Phase 1 INLIGHT Clinical Trial Of WVE-007 In Obesity . (RTTNews) - Wave Life Sciences Ltd. (WVE) an RNA medicines-focused clinical-stage biotechnology firm is set to announce interim data from its ongoing Phase 1 clinical trial evaluating WVE-007 an investigational drug for the treatment of obesity dubbed INLIGHT on December 8
Mon Dec 8, 2025
Are You Looking for a Top Momentum Pick? Why nLight (LASR) is a Great Choice. Does nLight (LASR) have what it takes to be a top stock pick for momentum investors? Lets find out.
Fri Dec 5, 2025
Cree LED and SANlight Partner to Advance High-Efficiency Horticulture Lighting. a brand (Nasdaq: ) and SANlight GmbH Schruns Austria today announced a partnership under which SANlight will use Cree LED'.s J Series®. products in its new STIXX-Series luminaires.This press release features multimedia. View the full release here: Developed for applications with limited space the STIXX fixtures feature a slim space-saving design with module efficiency of up to 3.1 μmol/J. Backed by LM-80 te
Tue Dec 2, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
LASR Stock trends
LASR Stock performance
LASR Stock analysis
LASR investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.